These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 15998960)

  • 1. Effectiveness and cost-effectiveness of antibiotic treatments for community acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB).
    Lavoie F; Blais L; Castilloux AM; Scalera A; LeLorier J
    Can J Clin Pharmacol; 2005; 12(2):e212-7. PubMed ID: 15998960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs of treating lower respiratory tract infections.
    Monte SV; Paolini NM; Slazak EM; Schentag JJ; Paladino JA
    Am J Manag Care; 2008 Apr; 14(4):190-6. PubMed ID: 18402511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
    Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA
    Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection.
    Quenzer RW; Pettit KG; Arnold RJ; Kaniecki DJ
    Am J Manag Care; 1997 Jul; 3(7):1027-36. PubMed ID: 10173367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of health care resource utilization after macrolide treatment failure: results from a large, population-based cohort with acute sinusitis, acute bronchitis, and community-acquired pneumonia.
    Wu JH; Howard DH; McGowan JE; Frau LM; Dai WS
    Clin Ther; 2004 Dec; 26(12):2153-62. PubMed ID: 15823779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
    Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
    Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis.
    Marras TK; Nopmaneejumruslers C; Chan CK
    Am J Med; 2004 Mar; 116(6):385-93. PubMed ID: 15006587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A pharmacoeconomic study of in-hospital treatment against community-acquired pneumonia].
    Bermejo Vicedo T; Torralba Arranz A; Hidalgo Correas FJ; Millán Santos I; Rodríguez Morradan B
    Farm Hosp; 2004; 28(1):29-35. PubMed ID: 15012176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers to the effective management of respiratory tract infections in the community.
    Saginur R
    Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.
    File TM; Monte SV; Schentag JJ; Paladino JA; Klugman KP; Lavin B; Yu VL; Singer ME; Adelman MH
    Int J Antimicrob Agents; 2009 Jan; 33(1):58-64. PubMed ID: 18835762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting.
    Malcolm C; Marrie TJ
    Arch Intern Med; 2003 Apr; 163(7):797-802. PubMed ID: 12695270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
    Cantón R; Lode H; Graninger W; Milkovich G
    Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S115-27. PubMed ID: 16904873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailored interventions to improve antibiotic use for lower respiratory tract infections in hospitals: a cluster-randomized, controlled trial.
    Schouten JA; Hulscher ME; Trap-Liefers J; Akkermans RP; Kullberg BJ; Grol RP; van der Meer JW
    Clin Infect Dis; 2007 Apr; 44(7):931-41. PubMed ID: 17342644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of spiramycin and clarithromycin for community-acquired lower respiratory tract infections.
    Rocha RT; Awad CE; Ali A; Matyas R; Vital AC; Silva CO; Dainesi SM; Salazar MS; Nakatani J
    Int J Clin Pract; 1999 Sep; 53(6):433-6. PubMed ID: 10622070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood cultures do not change management in hospitalized patients with community-acquired pneumonia.
    Ramanujam P; Rathlev NK
    Acad Emerg Med; 2006 Jul; 13(7):740-5. PubMed ID: 16766742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
    Martin M; Moore L; Quilici S; Decramer M; Simoens S
    Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance.
    Martin M; Quilici S; File T; Garau J; Kureishi A; Kubin M
    J Antimicrob Chemother; 2007 May; 59(5):977-89. PubMed ID: 17395688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: A retrospective data analysis.
    Jackson J; Fernandes AW; Nelson W
    Clin Ther; 2006 Sep; 28(9):1462-71. PubMed ID: 17062318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.